Postglucose growth hormone nadir and insulin-like growth factor-1 in naïve-active acromegalic patients: do these parameters always correlate?

Ribeiro‐Oliveira, Antônio; Faje, Alex; Barkan, Ariel L.

doi:10.1590/s0004-27302011000700011

Cited by 9 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, we observed no significant differences of plasma growth hormone levels in the CPO group compared with the placebo group. We also evaluated IGF-1 levels at baseline and after 8 weeks of supplementation because IGF-1 levels reflect growth hormone secretion [15]. No statistically significant difference between CPO and placebo groups was observed.…”

Section: Resultsmentioning

confidence: 99%

“…In addition to the direct effects of growth hormone to several tissues, it also elicits indirect effects mediated by insulin-like growth factor-1 (IGF-1) [12]. Plasma IGF-1 levels correlate with plasma growth hormone levels, as production of IGF-1 by the liver is stimulated by growth hormone [14,15]. Similar to growth hormone, IGF-1 activates cell growth in several tissues including bone [16], muscle [17], and skin [18,19], whereby it contributes to both epidermal or dermal skin development and maintenance.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Composite Supplement Containing Collagen Peptide and Ornithine on Skin Conditions and Plasma IGF-1 Levels—A Randomized, Double-Blind, Placebo-Controlled Trial

2018

View full text Add to dashboard Cite

Aging-associated changes of skin conditions are a major concern for maintaining quality of life. Therefore, the improvement of skin conditions by dietary supplementation is a topic of public interest. In this study, we hypothesized that a composite supplement containing fish derived-collagen peptide and ornithine (CPO) could improve skin conditions by increasing plasma growth hormone and/or insulin-like growth factor-1 (IGF-1) levels. Twenty-two healthy Japanese participants were enrolled in an 8-week double-blind placebo-controlled pilot study. They were assigned to either a CPO group, who were supplemented with a drink containing CPO, or an identical placebo group. We examined skin conditions including elasticity and transepidermal water loss (TEWL), as well as plasma growth hormone and IGF-1 levels. Skin elasticity and TEWL were significantly improved in the CPO group compared with the placebo group. Furthermore, only the CPO group showed increased plasma IGF-1 levels after 8 weeks of supplementation compared with the baseline. Our results might suggest the novel possibility for the use of CPO to improve skin conditions by increasing plasma IGF-1 levels.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effects of Composite Supplement Containing Collagen Peptide and Ornithine on Skin Conditions and Plasma IGF-1 Levels—A Randomized, Double-Blind, Placebo-Controlled Trial

2018

View full text Add to dashboard Cite

show abstract

“…In part, the differences in the published cut-offs are related to differences in the assays used, although most guidelines do not specify the assay used to generate the GH concentrations stated. Some authors have published convincing evidence that prevalence of acromegaly as well as percentages for remission largely depend on cut-off values used [ 60 , 61 , 64 , 65 , 69 , 70 ]. More recent publications on studies using modern, more specific GH assays calibrated against the latest recombinant standard clearly indicated that the above mentioned cut.-off of 1 ng/mL is inappropriately high and should be adapted for modern assays.…”

Section: Impact Of Molecular Heterogeneity On Gh Measurement In Clinimentioning

confidence: 99%

Growth hormone: isoforms, clinical aspects and assays interference

Schweizer

Ribeiro‐Oliveira

Bidlingmaier

2018

Clin Diabetes Endocrinol

View full text Add to dashboard Cite

The measurement of circulating concentrations of growth hormone (GH) is an indispensable tool in the diagnosis of both GH deficiency and GH excess. GH is a heterogeneous protein composed of several molecular isoforms, but the physiological role of these different isoforms has not yet been fully understood. The 22KD GH (22 K-GH) is the main isoform in circulation, followed by 20KD GH (20 K-GH) and other rare isoforms. Studies have been performed to better understand the biological actions of the different isoforms as well as their importance in pathological conditions. Generally, the non-22 K- and 20 K-GH isoforms are secreted in parallel to 22 K-GH, and only very moderate changes in the ratio between isoforms have been described in some pituitary tumors or during exercise. Therefore, in a diagnostic approach, concentrations of 22 K-GH accurately reflect total GH secretion. On the other hand, the differential recognition of GH isoforms by different GH immunoassays used in clinical routine contributes to the known discrepancy in results from different GH assays. This makes the application of uniform decision limits problematic. Therefore, the worldwide efforts to standardize GH assays include the recommendation to use 22 K-GH specific GH assays calibrated against the pure 22 K-GH reference preparation 98/574. Adoption of this recommendation might lead to improvement in diagnosis and follow-up of pathological conditions, and facilitate the comparison of results from different laboratories.

show abstract

“…In treatment-naïve, biochemically active patients, discordance appears to be greatest in those with only mildly elevated GH output, leading to a high false negative rate with GH suppression measurement [19]. Increased discordance is also seen at the other extreme in patients with particularly high GH levels [20]. In patients treated with pegvisomant, only IGF-1 remains a reliable marker of disease activity, as GH concentrations remain elevated [3, 16].…”

Section: Biochemical Versus Symptom Controlmentioning

confidence: 99%

Multiple facets in the control of acromegaly

et al. 2013

View full text Add to dashboard Cite

AimsThe current article provides a brief overview of the criteria for defining disease control in acromegaly.MethodsThis was a retrospective, narrative review of previously published evidence chosen at the author’s discretion along with an illustrative case study from Latin America.Findings and ConclusionsIn the strictest sense, “cure” in acromegaly is defined as complete restoration of normal pulsatile growth hormone secretion, although this is rarely achieved. Rather than “cure”, as such, it is more appropriate to refer to disease control and remission, which is defined mainly in terms of specific biochemical targets (for growth hormone and insulin-like growth factor-1) that predict or correlate with symptoms, comorbidities and mortality. However, optimal management of acromegaly goes beyond biochemical control to include control of tumour growth (which may be independent of biochemical control) and comprehensive management of the symptoms and comorbidities typically associated with the disease, as these may not be adequately managed with acromegaly-specific therapy alone.

show abstract

Postglucose growth hormone nadir and insulin-like growth factor-1 in naïve-active acromegalic patients: do these parameters always correlate?

Cited by 9 publications

References 16 publications

Effects of Composite Supplement Containing Collagen Peptide and Ornithine on Skin Conditions and Plasma IGF-1 Levels—A Randomized, Double-Blind, Placebo-Controlled Trial

Effects of Composite Supplement Containing Collagen Peptide and Ornithine on Skin Conditions and Plasma IGF-1 Levels—A Randomized, Double-Blind, Placebo-Controlled Trial

Growth hormone: isoforms, clinical aspects and assays interference

Multiple facets in the control of acromegaly

Contact Info

Product

Resources

About